Did you know that it is possible to give an opinion on how many options a Multiple Myeloma patient may have for their treatment?
The public health system currently has fewer options than it could
Until May 20 You can give your opinion through Public Consultation No. 18, referring to Clinical Protocol and Therapeutic Guidelines (PCDT) of Multiple Myeloma.
CLICK HERE TO PARTICIPATE IN THE PUBLIC CONSULTATION
👉 This is an opportunity to contribute to transforming the reality of thousands of patients with Multiple Myeloma in the public health system 👍
O Multiple Myeloma is one of the priority guidelines in the Ministry of Health and, therefore, the evaluation of the PCDT is part of the efforts to advance the diagnosis and treatment of patients.
🔹 What are PCDT?
Clinical Protocols and Therapeutic Guidelines (PCDT) They are documents that establish criteria for the diagnosis, treatment appropriate, Dosages recommended among other topics To be followed by SUS managers (1). That's why social participation is so important.
And so, the Public Consultation of the PCDT is an opportunity to Health professionals, patients, caregivers, and patients' families express their opinion and make the contribution - scientific and/or experience - that will greatly contribute to the construction of this new national protocol.
🔹 Understand:
👉 The current proposal of the PCDT does not include all the options approved in Brazil for the treatment of patients, excluding a monoclonal antibody considered one of the fundamental therapeutic classes of modern treatment for this type of patient (2,3);
👉 The use of effective combinations at the beginning of the treatment journey may prolong the reduction or disappearance of symptoms and signs of multiple myeloma and increase the chances of a positive long-term outcome (4);
👉 And since multiple myeloma is still a disease that remains incurable and with multiple relapses, it is evident that it is necessary explore new mechanisms of action in your treatment.
👉 The new drugs make it possible to deepen the response and increase the time of remission (5,6,7).
🔹Below, we present the possible schemes provided for in the PCDT under Public Consultation:
🔹 How to contribute to the Public Consultation of the PCDT?
👉 Access Public Consultation No. 18 through the link above or by searching the Participa + Brazil website;
👉 Log in with the same password you use when consulting your INSS or Digital Work Card;
👉 When accessing the questionnaire, pay attention to questions 10, 11 and 12 to contribute quality data:
10. What did you think of this proposal presented by Conitec?
11. Would you like to change or add some information to the text?
12. Would you like to comment on any other aspect?
We count on your contribution.
REFERENCES
- CONITEC. Clinical Protocols and Therapeutic Guidelines — PCDT. Available at: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/p/pcdt — Accessed in April 2024
- CONITEC. Diagnostic and Therapeutic Guidelines Recommendation Report. Available in: https://www.gov.br/conitec/pt-br/midias/consultas/relatorios/2022/20220526_ddt_mieloma_multiplo_cp.pdf — Accessed in April 2024
- Costa LJ, Hungary V, Mohty M, Mateos M-V. How I treat triple-class refractory multiple myeloma. Br J Haematol. 2022; 198:244 —256. doi:10.1111/bjh.18185
- Kumar SK et al. Multiple myeloma. Nat Rev Dis Primers. 2017 Jul 20; 3:17:04
- Kurtin, S. E. Relapsed or relapsed/refractory multiple myeloma. J Adv Pract Oncol 4. Suppl 1 (2013) :5-14.
- Rodriguez-Otero et al., Cancer Treatment Reviews 100 (2021) 102284
- Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017; 281:365 —382
